Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
220.07%
↑ 671% above average
Average (39q)
28.54%
Historical baseline
Range
High:1031.86%
Low:-374.69%
CAGR
+7.5%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | 220.07% |
| Q2 2025 | -86.89% |
| Q1 2025 | 1031.86% |
| Q4 2024 | -22.03% |
| Q3 2024 | 6.00% |
| Q2 2024 | -10.33% |
| Q1 2024 | 8.80% |
| Q4 2023 | -0.80% |
| Q3 2023 | -19.29% |
| Q2 2023 | 2.87% |
| Q1 2023 | 126.25% |
| Q4 2022 | -374.69% |
| Q3 2022 | 9.12% |
| Q2 2022 | -7.76% |
| Q1 2022 | -49.68% |
| Q4 2021 | 7.70% |
| Q3 2021 | 6.17% |
| Q2 2021 | -10.77% |
| Q1 2021 | -18.42% |
| Q4 2020 | 70.51% |
| Q3 2020 | 0.95% |
| Q2 2020 | 7.07% |
| Q1 2020 | -36.29% |
| Q4 2019 | 35.82% |
| Q3 2019 | 12.52% |
| Q2 2019 | 8.18% |
| Q1 2019 | 27.70% |
| Q4 2018 | 61.23% |
| Q3 2018 | -10.63% |
| Q2 2018 | -17.17% |
| Q1 2018 | -14.20% |
| Q4 2017 | 81.40% |
| Q3 2017 | -1.31% |
| Q2 2017 | -44.40% |
| Q1 2017 | 35.35% |
| Q4 2016 | 1.63% |
| Q3 2016 | 39.89% |
| Q2 2016 | 12.56% |
| Q1 2016 | 39.51% |
| Q4 2015 | 13.08% |